Verrica Pharmaceuticals Inc (VRCA)

Currency in USD
0.70
-0.02(-2.77%)
Closed·
After Hours
0.700.00(-0.51%)
·

VRCA Earnings

Latest Release
May 13, 2025
EPS / Forecast
-0.08 / -0.11
Revenue / Forecast
3.44M / 2.48M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
06/2025--/-0.09--/4.11M----Free Sign Up
03/2025-0.08/-0.113.44M/2.48M+27.27%+38.71%Free Sign Up
12/2024-0.24/-0.3340K/532.75K+20%-36.18%Free Sign Up
09/2024-0.43/-0.38-1,780,000/5.76M-13.16%-130.9%Free Sign Up
06/2024-0.37/-0.415.18M/4.58M+9.76%+13.1%Free Sign Up
03/2024-0.38/-0.433.83M/2.67M+11.63%+43.45%Free Sign Up
12/2023-0.53/-0.531.99M/1.99M0%0%Free Sign Up
09/2023-0.54/-0.362.92M/454.07K-50%+543.07%Free Sign Up
06/2023-0.24/-0.21180K/257.6K-14.29%-30.12%Free Sign Up
03/2023-0.15/-0.1537K/37K0%0%Free Sign Up

All numbers in USD

Verrica Pharmaceuticals Inc Earnings Call Summary for Q1/2025

  • Q1 2025 revenue reached $3.4M, driven by WICANT's 16.7% sequential growth in dispensed units, exceeding 10,000 quarterly for the first time
  • GAAP net loss of $9.7M ($0.10/share); Non-GAAP net loss of $7.8M ($0.08/share); Cash and equivalents at $29.6M as of March 31, 2025
  • Stock rose 8.63% in regular trading but fell 7.09% after hours; currently trades at $0.51, down 95% over the past year
  • Company focuses on WICANT commercialization and expanding to independent pharmacies; advancing BP315 for basal cell carcinoma
  • Analysts project 107% revenue growth this fiscal year; price targets range $2-$5; average recommendation 2.33
Last Updated: 13/05/2025, 22:20
Read Full Transcript

FAQ

What Is Verrica Pharmaceuticals's Earnings Per Share (TTM)?

The Verrica Pharmaceuticals EPS (TTM) is -1.03.

When Is The Next Verrica Pharmaceuticals Earnings Date?

Verrica Pharmaceuticals will release its next earnings report on 11 Aug 2025.

What Is Verrica Pharmaceuticals’s Revenue Forecasts For Upcoming Quarters?

Verrica Pharmaceuticals’s revenue forecast is 4.11M.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.